Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
Pemetrexed (Alimta)
Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?
Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients[…]
ONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial
Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12,[…]
Immunotherapy Treatment Durvalumab Enters Phase II Clinical Trial
While there is no cure for mesothelioma, those who are able to withstand surgery in general may have a better chance of survival, as the cancer is being physically removed. However, mesothelioma is a difficult cancer and often surgery is not an option, and the cancer is unresectable. The success[…]
Effective Chemotherapy May Rest Upon Reducing Overactive Enzyme
Chemotherapy for mesothelioma patients has been notoriously difficult and the cancer continues to be overwhelmingly unresponsive to such treatment in many cases. However, researchers and scientists have been continually investigating new techniques that involve adjusting how chemotherapy reacts on a cellular level. A study published in the Frontiers in Pharmacology[…]
ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended
A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy.[…]
Bevacizumab – A Positive Treatment with Serious Side Effects
Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen[…]
The Effectiveness of Cisplatin and Pemetrexed in Pericardial Mesothelioma
Out of all the types of mesothelioma, pericardial mesothelioma is one of the rarest forms, accounting for only 0.002% of all known diagnosed mesothelioma cases. Mesothelioma is caused by asbestos exposure, and despite this knowledge and years of research, scientists and researchers still do not have a clear answer as[…]
Determining and Prolonging Survival Rates In Mesothelioma
The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown. The latest study to be published in Histopathology investigates what it is in the body that determines a[…]
Mesothelioma Treatments Used Alongside Surgery – A Clinical Trial
Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and[…]